• Assistant Professor, Global Health
Patty Pavlinac

Box 359931
325 Ninth Avenue
Seattle, WA 98104
United States

Phone Number: 
206-616-8326
Email: 
ppav@uw.edu
Select from the following:
Biography 

Patricia Pavlinac, PhD MS, is an epidemiologist and co-director of the Gut Health and Child Survival Scientific Priority Area. Dr. Pavlinac’s research aims to identify and test interventions to halt morbidity and mortality attributed to enteric and diarrheal diseases. Her other research interests include antibiotic resistance and pediatric tuberculosis.

Education 
  • MS (University of Washington)
  • BA (Colgate University)
  • PhD (University of Washington)
Country Affiliations 
Health Topics 
  • Child and Adolescent Health (incl. Pediatrics)
  • Child Mortality
  • Diarrheal Diseases
  • Epidemiology
  • Infectious Diseases (other than STDs)
  • Maternal Child Health (incl. Reproductive Health)
  • TB
DGH Centers, Programs and Initiatives and Affiliated Organizations 
Publications 

Tickell KD, Brander RL, Atlas HE, Pernica JM, Walson JL, Pavlinac PB. Identification and management of Shigella infection in children with diarrhoea: a systematic review and meta-analysis. Lancet Global Health 2017; 5: e1235-e1248; PMC5695759

Pavlinac PB, Singa BO, John-Stewart GC, Richardson BA, Brander RL, McGrath CJ, Tickell KD, Amondi M, Rwigi D, Babigumira JB, Kariuki S, Nduati R, Walson JL. Azithromycin to prevent post-discharge morbidity and mortality in Kenyan children: a protocol for a randomised, double-blind, placebo-controlled trial (the Toto Bora trial). BMJ Open 2017; 7: e019170; PMC5778294

Brander RL, Walson JL, John-Stewart GC, Naulikha JM, Ndonye J, Kipkemoi N, Rwigi D, Singa BO, Pavlinac PB. Correlates of multi-drug non-susceptibility in enteric bacteria isolated from Kenyan children with acute diarrhea. PLoS Neglected Tropical Diseases 2017; 11: e0005974; PMC5638605

LaCourse SM, Cranmer LM, Njuguna IN, Gatimu J, Stern J, Maleche-Obimbo E, Walson JL, Wamalwa D, John-Stewart G, Pavlinac P, 2018. Urine TB lipoarabinomannan (LAM) predicts mortality in hospitalized HIV-infected children. Clin Infect Dis 2018;66(11): 1798-1801; PMC5961239